These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37311667)

  • 41. Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a 2012 calculation for a midwestern health referral region.
    Hoang A; Shen C; Zheng J; Taylor S; Groh WJ; Rosenman M; Buxton AE; Chen PS
    Heart Rhythm; 2014 May; 11(5):849-55. PubMed ID: 24566233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta-Analysis of Randomized Trials and Propensity Score-Matched Studies.
    Fong KY; Ng CJR; Wang Y; Yeo C; Tan VH
    J Am Heart Assoc; 2022 Jun; 11(11):e024756. PubMed ID: 35656975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.
    Rassi FM; Minohara L; Rassi A; Correia LCL; Marin-Neto JA; Rassi A; da Silva Menezes A
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1213-1223. PubMed ID: 31648747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
    Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implantable cardioverter defibrillator shocks are prospective predictors of anxiety.
    Schulz SM; Massa C; Grzbiela A; Dengler W; Wiedemann G; Pauli P
    Heart Lung; 2013; 42(2):105-11. PubMed ID: 23110854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exercise-based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator.
    Nielsen KM; Zwisler AD; Taylor RS; Svendsen JH; Lindschou J; Anderson L; Jakobsen JC; Berg SK
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD011828. PubMed ID: 30746679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence and predictors of implantable cardioverter-defibrillator therapy and its complications in idiopathic ventricular fibrillation patients.
    Blom LJ; Visser M; Christiaans I; Scholten MF; Bootsma M; van den Berg MP; Yap SC; van der Heijden JF; Doevendans PA; Loh P; Postema PG; Barge-Schaapsveld DQ; Hofman N; Volders PGA; Wilde AA; Hassink RJ
    Europace; 2019 Oct; 21(10):1519-1526. PubMed ID: 31114860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
    Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of cognitive behavioral therapy on mood symptoms in patients with implantable cardioverter defibrillator: A systematic review and meta-analysis.
    Li Z; Liu Y; Wang J; Zhang C; Liu Y
    Complement Ther Clin Pract; 2022 May; 47():101570. PubMed ID: 35358944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characteristics associated with anxiety, depressive symptoms, and quality-of-life in a large cohort of implantable cardioverter defibrillator recipients.
    Thylén I; Dekker RL; Jaarsma T; Strömberg A; Moser DK
    J Psychosom Res; 2014 Aug; 77(2):122-7. PubMed ID: 25077853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: a meta-analysis.
    Scott PA; Silberbauer J; McDonagh TA; Murgatroyd FD
    Heart Rhythm; 2014 May; 11(5):828-35. PubMed ID: 24530622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
    Magnusson P; Gadler F; Liv P; Mörner S
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1088-94. PubMed ID: 26178879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mindfulness Is Associated with Lower Depression, Anxiety, and Post-Traumatic Stress Disorder Symptoms and Higher Quality of Life in Patients with an Implantable Cardioverter-Defibrillator-A Cross-Sectional Study.
    Dörner M; von Känel R; König N; Pazhenkottil AP; Altwegg R; Nager L; Attanasio V; Guth L; Zirngast S; Menzi A; Zuccarella-Hackl C; Princip M
    Healthcare (Basel); 2024 May; 12(11):. PubMed ID: 38891193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implantable cardioverter-defibrillators and survival in advanced heart failure patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis.
    Elkaryoni A; Badarin FA; Khan MS; Ellakany K; Potturi N; Poonia J; Kennedy KF; Magalski A; Sperry BW; Wimmer AP
    Europace; 2019 Sep; 21(9):1353-1359. PubMed ID: 31086951
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Assessment of Transvenous versus Subcutaneous Implantable Cardioverter-defibrillator Therapy Outcomes: An Updated Systematic Review and Meta-analysis.
    Nso N; Nassar M; Lakhdar S; Enoru S; Guzman L; Rizzo V; Munira MS; Radparvar F; Thambidorai S
    Int J Cardiol; 2022 Feb; 349():62-78. PubMed ID: 34801615
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.